title: Pharmaceutical erythropoietin use in patients with cancer: is it time to abandon ship or just drop anchor?
authors.forename: Ayalew
authors.initials: A
authors.lastname: Tefferi
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D001792:Blood Platelets / Q000187:drug effects; D004921:Erythropoietin / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000378:metabolism / Q000401:mortality; D009389:Neovascularization, Pathologic / Q000139:chemically induced; D017467:Receptors, Erythropoietin / Q000378:metabolism; D013923:Thromboembolism / Q000139:chemically induced
chemical_list: D006397:Hematinics; D006454:Hemoglobins; D017467:Receptors, Erythropoietin; D004921:Erythropoietin